Annelie Johansson
Chesterford Research Park
Cambridge, ENG, United Kingdom
Cambridge, ENG, United Kingdom
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 19 publications
Tamoxifen therapy benefit in luminal A and B breast cancer with 20-year follow-up.
Journal: Journal of the National Cancer Institute
Published: October 13, 2025
An antibody-drug conjugate designed through clone and isotype selection restricts the growth of CSPG4-expressing triple-negative breast cancer.
Journal: NPJ precision oncology
Published: August 31, 2025
Response to Zhu, Bu, and Zhu.
Journal: Journal of the National Cancer Institute
Published: July 07, 2025
Progesterone receptor (PR) intra-tumor heterogeneity in premenopausal breast cancer: A secondary analysis of a randomized trial.
Journal: International journal of cancer
Published: October 25, 2024
Temporally discordant chromatin accessibility and DNA demethylation define short- and long-term enhancer regulation during cell fate specification.
Journal: Cell reports
Published: September 26, 2024
Temporally discordant chromatin accessibility and DNA demethylation define short and long-term enhancer regulation during cell fate specification.
Journal: bioRxiv : the preprint server for biology
Published: September 10, 2024
Differential long-term tamoxifen therapy benefit by menopausal status in breast cancer patients: secondary analysis of a controlled randomized clinical trial.
Journal: Journal of the National Cancer Institute
Published: May 02, 2024
Anti-EGFR Antibody-Drug Conjugate Carrying an Inhibitor Targeting CDK Restricts Triple-Negative Breast Cancer Growth.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: October 12, 2023
Clinically relevant gene signatures provide independent prognostic information in older breast cancer patients.
Journal: Breast cancer research : BCR
Published: June 21, 2023
Prognostic and Predictive Significance of Stromal Tumor-Infiltrating Lymphocytes (sTILs) in ER-Positive/HER2-Negative Postmenopausal Breast Cancer Patients.
Journal: Cancers
Published: August 22, 2022
Twenty-Year Benefit From Adjuvant Goserelin and Tamoxifen in Premenopausal Patients With Breast Cancer in a Controlled Randomized Clinical Trial.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: July 21, 2022
Last Updated: 09/26/2026